The Experts below are selected from a list of 321 Experts worldwide ranked by ideXlab platform
D. Kraft - One of the best experts on this subject based on the ideXlab platform.
-
Serologic and skin test diagnosis of birch Pollen Allergy with recombinant Bet v 1, the chief allergen of birch
Pneumologie (Stuttgart Germany), 1996Co-Authors: G Menz, C. Ebner, Christiane Dolecek, Fatima Ferreira, M Moser, T Schneider, M Suter, U. Schönheit-kenn, George Boltz-nitulescu, D. KraftAbstract:BACKGROUND Type I Allergy represents a severe health problem in industrialized countries where up to 20% of the population suffers from allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis, leading to death. OBJECTIVE The aim of this study was to evaluate recombinant Bet v 1, the major birch Pollen allergen for in vivo and in vitro diagnosis of birch Pollen Allergy. METHODS A group of 51 birch Pollen allergic patients and eight non-allergic control individuals were tested for birch Pollen Allergy by skin-prick and intradermal testing, comparing commercial birch Pollen extracts with recombinant Bet v 1. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and immunoblotting. RESULTS Recombinant Bet v 1 allowed accurate in vivo and in vitro diagnosis of tree Pollen Allergy in 49/51 patients tested. No false positive results were obtained in any in vitro assay system (ELISA, Westernblot) or by skin testing (skin-prick, intradermal test) with recombinant Bet v 1. CONCLUSION Our results document that recombinant Bet v 1 produced in bacterial expression systems allows accurate in vitro and in vivo diagnosis of birch Pollen Allergy in > 95% of birch Pollen allergic patients.
-
serological and skin test diagnosis of birch Pollen Allergy with recombinant bet v i the major birch Pollen allergen
Clinical & Experimental Allergy, 1996Co-Authors: G Menz, C. Ebner, Christiane Dolecek, U Schonheitkenn, Fatima Ferreira, M Moser, T Schneider, M Suter, George Boltznitulescu, D. KraftAbstract:BACKGROUND: Type I Allergy represents a severe health problem in industrialized countries where up to 20% of the population suffer from allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis, leading to death. OBJECTIVE: The aim of this study was to evaluate recombinant Bet v I, the major birch Pollen allergen for in vivo and in vitro diagnosis of birch Pollen Allergy. METHODS: A group of 51 birch Pollen allergic patients and eight non-allergic control individuals were tested for birch Pollen Allergy by skin-prick and intradermal testing, comparing commercial birch Pollen extracts with recombinant Bet v I. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and immunoblotting. RESULTS: Recombinant Bet v I allowed accurate in vivo and in vitro diagnosis of tree Pollen Allergy in 49/51 patients tested. No false positive results were obtained in any in vitro assay system (ELISA, Western blot) or by skin testing (skin-prick, intradermal test) with recombinant Bet v I. CONCLUSION: Our results document that recombinant Bet v I produced in bacterial expression systems allows accurate in vitro and in vivo diagnosis of birch Pollen Allergy in > 95% of birch Pollen allergic patients.
-
Serological and skin-test diagnosis of birch Pollen Allergy with recombinant Bet v I, the major birch Pollen allergen.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1996Co-Authors: G Menz, C. Ebner, Christiane Dolecek, Fatima Ferreira, M Moser, T Schneider, M Suter, U. Schönheit-kenn, George Boltz-nitulescu, D. KraftAbstract:Summary Background Type I Allergy represents a severe health problem in industrialized countries where up to 20% of the population suffer froin allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis. leading to death. Objective The aim of this study was to evaluate recombinant Bet v I, the major birch Pollen allergen for in vivo and in vitro diagnosis of birch Pollen Allergy. Methods A group of 51 birch Pollen allergic patients and eight non-allergic control individuals were tested for birch Pollen Allergy by skin-prick and intradennal testing, comparing commercial birch Pollen extracts with recombinant Bet v I. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and immunoblotting. Results Recombinant Bet v I allowed accurate in vivo and in vitro diagnosis of tree Pollen Allergy in 49/51 patients tested. No false positive results were obtained in any in vitro assay system (ELISA. Westernblot) or by skin testing (skin-prick, intradermal test) with recombinant Bet v I. Conclusion Our results document that recombinant Bet v I produced in bacterial expression systems allows accurate in vitro and in vivo diagnosis of birch Pollen Allergy in > 95% of birch Pollen allergic patients.
-
Diagnosis of grass Pollen Allergy with recombinant timothy grass (Phleum pratense) Pollen allergens.
International archives of allergy and immunology, 1992Co-Authors: Rudolf Valenta, Susanne Vrtala, C. Ebner, D. Kraft, Otto ScheinerAbstract:In order to establish a test system for grass Pollen Allergy based on the use of recombinant allergens we chose timothy grass (Phleum pratense), a widely spread grass, as a model. From a lambda gt11 cDNA expression library that we had constructed from Pollen RNA of timothy grass (P. pratense), we had obtained with serum IgE from a grass Pollen-allergic individual 60 IgE-binding clones. By differential testing with sera from different grass Pollen-allergic patients, we selected three distinct clones encoding Phl p I (group I), Phl p V (group V) and profilin from timothy grass, which when used together allowed the diagnosis of grass Pollen Allergy in 97 out of 98 tested grass Pollen-allergic patients employing a simple plaque lift technique. This recombinant test based on plaque lifts containing allergen-beta-galactosidase fusion proteins was compared with IgE immunoblots using crude Pollen protein extracts from timothy grass. Both methods were in good agreement with RAST scores and clinical data, and proofed to be useful for the diagnosis of grass Pollen Allergy. Our results further indicate that a limited panel of only two recombinant grass Pollen allergens, Phl p I and Phl p V, together with the plant panallergen profilin could be sufficient for the diagnosis and possibly immunotherapy of grass Pollen Allergy.
Rudolf Valenta - One of the best experts on this subject based on the ideXlab platform.
-
Marker allergens and panallergens in tree and grass Pollen Allergy
Allergo Journal International, 2015Co-Authors: Katharina Gangl, Rudolf Valenta, Verena Niederberger, Andreas NandyAbstract:Detection of specific IgE using component resolved diagnostics (CRD) identifies the underlying allergen source in suspected cases of tree and grass Pollen Allergy. Suitable marker allergens can be used to distinguish genuine sensitization to tree or grass Pollen from cross-reactivity to Pollen panallergens (e. g. profilin and polcalcins) and to overcome the lack of analytical specificity of natural allergen extracts. In patients reacting with a variety of Pollen extracts suspected of polysensitization, CRD allows allergen specific diagnosis regardless of the confounding effect of panallergenic cross-reactivity and administration of tailored, specific immunotherapy. In this article, allergens indicating specific sensitization to grass and tree Pollen are described. Allergens defined as marker allergens for tree and grass Pollen Allergy are Bet v 1 (birch Pollen major allergen) for birch, beech and other trees from the Fagales order, Ole e 1 (olive Pollen major allergen) for olive and other trees including ash from the Oleaceae family, Pla a 1 (major allergen of the London plane tree) for plane trees, Cry j 1 (major allergen of the Japanese cedar), Cup a 1 (major allergen of the Arizona cypress) for cypress trees and Phl p 1 und 5 (Timothy grass major allergens) for sweet grasses including rye. Grass and tree Pollen allergens with serological and clinical cross-reactivity to a great number of allergen sources are also identified as possible confounding factors in allergen specific diagnosis with natural extracts. Structured diagnostic procedures for clinical routine work are proposed.
-
Skin test diagnosis of grass Pollen Allergy with a recombinant hybrid molecule
The Journal of Allergy and Clinical Immunology, 2007Co-Authors: C. Metz-favre, Margarete Focke-tejkl, Ashok Purohit, Birgit Linhart, Frederic De Blay, Rudolf Valenta, Gabrielle PauliAbstract:Background A recombinant hybrid molecule (HM) consisting of 4 major allergens from timothy grass (Phl p 1, 2, 5, and 6) was expressed in Escherichia coli , purified, and characterized regarding its immunologic properties. Objective We sought to determine whether the recombinant HM can be used for the diagnosis of grass Pollen Allergy by means of skin testing. Methods Skin prick testing was performed in 32 patients with grass Pollen Allergy and in 9 control individuals by using increasing concentrations (4, 12, 36, and 108 μg/mL) of the HM and using commercial grass Pollen extract. Specific IgE reactivities against the HM, grass Pollen extract, and a panel of purified grass Pollen allergens (recombinant Phl p 1, 2, 5, 6, 7, 12, and 13 and natural Phl p 4) were measured by means of ELISA, and timothy grass Pollen–specific IgE levels were determined by using ImmunoCAP. Results Grass Pollen Allergy was diagnosed in all patients by means of skin testing with the HM. No false-positive skin test responses were obtained in the control individuals. There was an excellent correlation between IgE levels obtained with the HM and natural grass Pollen extract measured by means of ELISA ( r = 0.98, P r = 0.98, P Conclusions The recombinant HM permitted accurate and specific in vivo diagnosis of grass Pollen Allergy in all tested patients. It can be considered a well-defined tool for the diagnosis and perhaps for immunotherapy of grass Pollen Allergy. Clinical implications A recombinant HM can replace traditional allergen extracts for skin test–based diagnosis of grass Pollen Allergy.
-
Transition from a Botanical to a Molecular Classification in Tree Pollen Allergy: Implications for Diagnosis and Therapy
International archives of allergy and immunology, 2004Co-Authors: Nadine Mothes, Friedrich Horak, Rudolf ValentaAbstract:Tree Pollens are among the most important allergen sources. Allergic cross-reactivity to Pollens of trees from various plant orders has so far been classified according to botanical relationships. In this context, cross-reactivities to Pollens of trees of the Fagales order (birch, alder, hazel, hornbeam, oak, chestnut), fruits and vegetables, between Pollens of the Scrophulariales (olive, ash, plantain, privet, lilac) and Pollens of the Coniferales (cedar, cypress, pine) are well established. The application of molecular biology methods for allergen characterization has revealed the molecular nature of many important tree Pollen allergens. We review the spectrum of tree Pollen allergens and propose a classification of tree Pollen and related allergies based on major allergen molecules instead of botanical relationships among the allergenic sources. This molecular classification suggests the major birch Pollen allergen, Bet v 1 as a marker for Fagales Pollen and related plant food allergies, the major olive Pollen allergen, Ole e 1, as a possible marker for Scrophulariales Pollen Allergy and the cedar allergens, Cry j 1 and Cry j 2, as potential markers for Allergy to Coniferales Pollens. We exemplify for Fagales Pollen Allergy and Bet v 1 that major marker allergens are diagnostic tools to determine the disease-eliciting allergen source. Information obtained by diagnostic testing with marker allergens will be important for the appropriate selection of patients for allergen-specific forms of therapy.
-
Diagnosis of grass Pollen Allergy with recombinant timothy grass (Phleum pratense) Pollen allergens.
International archives of allergy and immunology, 1992Co-Authors: Rudolf Valenta, Susanne Vrtala, C. Ebner, D. Kraft, Otto ScheinerAbstract:In order to establish a test system for grass Pollen Allergy based on the use of recombinant allergens we chose timothy grass (Phleum pratense), a widely spread grass, as a model. From a lambda gt11 cDNA expression library that we had constructed from Pollen RNA of timothy grass (P. pratense), we had obtained with serum IgE from a grass Pollen-allergic individual 60 IgE-binding clones. By differential testing with sera from different grass Pollen-allergic patients, we selected three distinct clones encoding Phl p I (group I), Phl p V (group V) and profilin from timothy grass, which when used together allowed the diagnosis of grass Pollen Allergy in 97 out of 98 tested grass Pollen-allergic patients employing a simple plaque lift technique. This recombinant test based on plaque lifts containing allergen-beta-galactosidase fusion proteins was compared with IgE immunoblots using crude Pollen protein extracts from timothy grass. Both methods were in good agreement with RAST scores and clinical data, and proofed to be useful for the diagnosis of grass Pollen Allergy. Our results further indicate that a limited panel of only two recombinant grass Pollen allergens, Phl p I and Phl p V, together with the plant panallergen profilin could be sufficient for the diagnosis and possibly immunotherapy of grass Pollen Allergy.
An Van Nieuwenhuyse - One of the best experts on this subject based on the ideXlab platform.
-
Exposure to green space and Pollen Allergy symptom severity: A case-crossover study in Belgium.
The Science of the total environment, 2021Co-Authors: Michiel Stas, Raf Aerts, Marijke Hendrickx, Andy Delcloo, Nicolas Dendoncker, Sebastien Dujardin, Catherine Linard, Tim Nawrot, An Van Nieuwenhuyse, Jean-marie AertsAbstract:The prevalence of Pollen Allergy has increased due to urbanization, climate change and air pollution. The effects of green space and air pollution on respiratory health of Pollen Allergy patients are complex and best studied in spatio-temporal detail. We tracked 144 adults sensitized to Betulaceae Pollen during the tree Pollen season (January-May) of 2017 and 2018 and assessed their spatio-temporal exposure to green space, allergenic trees, air pollutants and birch Pollen. Participants reported daily symptom severity scores. We extracted 404 case days with high symptom severity scores and matched these to 404 control days. The data were analyzed using conditional logistic regression with a 1:1 case-crossover design. Case days were associated with exposure to birch Pollen concentration (100 grains/m3) [adjusted odds ratio 1.045 and 95% confidence interval (1.014-1.078)], O3 concentration (10 μg/m3) [1.504 (1.281-1.766)] and PM10 concentration (10 μg/m3) [1.255 (1.007-1.565)] on the day of the severe Allergy event and with the cumulative exposure of one and two days before. Exposure to grass cover (10% area fraction) [0.655 (0.446-0.960)], forest cover (10% area fraction) [0.543 (0.303-0.973)] and density of Alnus (10%) [0.622 (0.411-0.942)] were protective for severe Allergy, but only on the day of the severe Allergy event. Increased densities of Betula trees (10%) were a risk factor [unadjusted OR: 2.014 (1.162-3.490)]. Exposure to green space may mitigate tree Pollen Allergy symptom severity but only when the density of allergenic trees is low. Air pollutants contribute to more severe Allergy symptoms. Spatio-temporal tracking allows for a more realistic exposure assessment. Copyright © 2021 Elsevier B.V. All rights reserved.
-
Residential green space and seasonal distress in a cohort of tree Pollen Allergy patients.
International journal of hygiene and environmental health, 2019Co-Authors: Raf Aerts, Michiel Stas, Marijke Hendrickx, Nicolas Dendoncker, Sebastien Dujardin, Naomi Vanlessen, Nicolas Bruffaerts, Lucie Hoebeke, Nelly D. Saenen, An Van NieuwenhuyseAbstract:Abstract Background Residential green space may improve human health, for example by promoting physical activity and by reducing stress. Conversely, residential green space may increase stress by emitting aeroallergens and exacerbating allergic disease. Here we examine impacts of exposure to residential green space on distress in the susceptible subpopulation of adults sensitized to tree Pollen allergens. Methods In a panel study of 88 tree Pollen Allergy patients we analyzed self-reported mental health (GHQ-12), perceived presence of allergenic trees (hazel, alder, birch) near the residence and residential green space area within 1 km distance [high (≥3 m) and low ( Results Short-term distress [mean GHQ-12 score 2.1 (95% confidence interval 1.5–2.7)] was higher in the study population than in the general population [1.5 (1.4–1.7)]. Residential green space had protective effects against short-term distress [high green, per combined surface area of 10 ha: adjusted odds ratio OR = 0.94 (95% confidence interval 0.90–0.99); low green, per 10 ha: OR = 0.85 (0.78–0.93)]. However, distress was higher in patients who reported perceived presence of allergenic trees near their residence [present vs. absent: OR = 2.04 (1.36–3.07)]. Conclusions Perceived presence of allergenic tree species in the neighbourhood of the residence of tree Pollen Allergy patients modulates the protective effect of residential green space against distress during the airborne tree Pollen season.
C. Ebner - One of the best experts on this subject based on the ideXlab platform.
-
Serologic and skin test diagnosis of birch Pollen Allergy with recombinant Bet v 1, the chief allergen of birch
Pneumologie (Stuttgart Germany), 1996Co-Authors: G Menz, C. Ebner, Christiane Dolecek, Fatima Ferreira, M Moser, T Schneider, M Suter, U. Schönheit-kenn, George Boltz-nitulescu, D. KraftAbstract:BACKGROUND Type I Allergy represents a severe health problem in industrialized countries where up to 20% of the population suffers from allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis, leading to death. OBJECTIVE The aim of this study was to evaluate recombinant Bet v 1, the major birch Pollen allergen for in vivo and in vitro diagnosis of birch Pollen Allergy. METHODS A group of 51 birch Pollen allergic patients and eight non-allergic control individuals were tested for birch Pollen Allergy by skin-prick and intradermal testing, comparing commercial birch Pollen extracts with recombinant Bet v 1. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and immunoblotting. RESULTS Recombinant Bet v 1 allowed accurate in vivo and in vitro diagnosis of tree Pollen Allergy in 49/51 patients tested. No false positive results were obtained in any in vitro assay system (ELISA, Westernblot) or by skin testing (skin-prick, intradermal test) with recombinant Bet v 1. CONCLUSION Our results document that recombinant Bet v 1 produced in bacterial expression systems allows accurate in vitro and in vivo diagnosis of birch Pollen Allergy in > 95% of birch Pollen allergic patients.
-
serological and skin test diagnosis of birch Pollen Allergy with recombinant bet v i the major birch Pollen allergen
Clinical & Experimental Allergy, 1996Co-Authors: G Menz, C. Ebner, Christiane Dolecek, U Schonheitkenn, Fatima Ferreira, M Moser, T Schneider, M Suter, George Boltznitulescu, D. KraftAbstract:BACKGROUND: Type I Allergy represents a severe health problem in industrialized countries where up to 20% of the population suffer from allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis, leading to death. OBJECTIVE: The aim of this study was to evaluate recombinant Bet v I, the major birch Pollen allergen for in vivo and in vitro diagnosis of birch Pollen Allergy. METHODS: A group of 51 birch Pollen allergic patients and eight non-allergic control individuals were tested for birch Pollen Allergy by skin-prick and intradermal testing, comparing commercial birch Pollen extracts with recombinant Bet v I. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and immunoblotting. RESULTS: Recombinant Bet v I allowed accurate in vivo and in vitro diagnosis of tree Pollen Allergy in 49/51 patients tested. No false positive results were obtained in any in vitro assay system (ELISA, Western blot) or by skin testing (skin-prick, intradermal test) with recombinant Bet v I. CONCLUSION: Our results document that recombinant Bet v I produced in bacterial expression systems allows accurate in vitro and in vivo diagnosis of birch Pollen Allergy in > 95% of birch Pollen allergic patients.
-
Serological and skin-test diagnosis of birch Pollen Allergy with recombinant Bet v I, the major birch Pollen allergen.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1996Co-Authors: G Menz, C. Ebner, Christiane Dolecek, Fatima Ferreira, M Moser, T Schneider, M Suter, U. Schönheit-kenn, George Boltz-nitulescu, D. KraftAbstract:Summary Background Type I Allergy represents a severe health problem in industrialized countries where up to 20% of the population suffer froin allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis. leading to death. Objective The aim of this study was to evaluate recombinant Bet v I, the major birch Pollen allergen for in vivo and in vitro diagnosis of birch Pollen Allergy. Methods A group of 51 birch Pollen allergic patients and eight non-allergic control individuals were tested for birch Pollen Allergy by skin-prick and intradennal testing, comparing commercial birch Pollen extracts with recombinant Bet v I. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and immunoblotting. Results Recombinant Bet v I allowed accurate in vivo and in vitro diagnosis of tree Pollen Allergy in 49/51 patients tested. No false positive results were obtained in any in vitro assay system (ELISA. Westernblot) or by skin testing (skin-prick, intradermal test) with recombinant Bet v I. Conclusion Our results document that recombinant Bet v I produced in bacterial expression systems allows accurate in vitro and in vivo diagnosis of birch Pollen Allergy in > 95% of birch Pollen allergic patients.
-
Diagnosis of grass Pollen Allergy with recombinant timothy grass (Phleum pratense) Pollen allergens.
International archives of allergy and immunology, 1992Co-Authors: Rudolf Valenta, Susanne Vrtala, C. Ebner, D. Kraft, Otto ScheinerAbstract:In order to establish a test system for grass Pollen Allergy based on the use of recombinant allergens we chose timothy grass (Phleum pratense), a widely spread grass, as a model. From a lambda gt11 cDNA expression library that we had constructed from Pollen RNA of timothy grass (P. pratense), we had obtained with serum IgE from a grass Pollen-allergic individual 60 IgE-binding clones. By differential testing with sera from different grass Pollen-allergic patients, we selected three distinct clones encoding Phl p I (group I), Phl p V (group V) and profilin from timothy grass, which when used together allowed the diagnosis of grass Pollen Allergy in 97 out of 98 tested grass Pollen-allergic patients employing a simple plaque lift technique. This recombinant test based on plaque lifts containing allergen-beta-galactosidase fusion proteins was compared with IgE immunoblots using crude Pollen protein extracts from timothy grass. Both methods were in good agreement with RAST scores and clinical data, and proofed to be useful for the diagnosis of grass Pollen Allergy. Our results further indicate that a limited panel of only two recombinant grass Pollen allergens, Phl p I and Phl p V, together with the plant panallergen profilin could be sufficient for the diagnosis and possibly immunotherapy of grass Pollen Allergy.
Raf Aerts - One of the best experts on this subject based on the ideXlab platform.
-
Exposure to green space and Pollen Allergy symptom severity: A case-crossover study in Belgium.
The Science of the total environment, 2021Co-Authors: Michiel Stas, Raf Aerts, Marijke Hendrickx, Andy Delcloo, Nicolas Dendoncker, Sebastien Dujardin, Catherine Linard, Tim Nawrot, An Van Nieuwenhuyse, Jean-marie AertsAbstract:The prevalence of Pollen Allergy has increased due to urbanization, climate change and air pollution. The effects of green space and air pollution on respiratory health of Pollen Allergy patients are complex and best studied in spatio-temporal detail. We tracked 144 adults sensitized to Betulaceae Pollen during the tree Pollen season (January-May) of 2017 and 2018 and assessed their spatio-temporal exposure to green space, allergenic trees, air pollutants and birch Pollen. Participants reported daily symptom severity scores. We extracted 404 case days with high symptom severity scores and matched these to 404 control days. The data were analyzed using conditional logistic regression with a 1:1 case-crossover design. Case days were associated with exposure to birch Pollen concentration (100 grains/m3) [adjusted odds ratio 1.045 and 95% confidence interval (1.014-1.078)], O3 concentration (10 μg/m3) [1.504 (1.281-1.766)] and PM10 concentration (10 μg/m3) [1.255 (1.007-1.565)] on the day of the severe Allergy event and with the cumulative exposure of one and two days before. Exposure to grass cover (10% area fraction) [0.655 (0.446-0.960)], forest cover (10% area fraction) [0.543 (0.303-0.973)] and density of Alnus (10%) [0.622 (0.411-0.942)] were protective for severe Allergy, but only on the day of the severe Allergy event. Increased densities of Betula trees (10%) were a risk factor [unadjusted OR: 2.014 (1.162-3.490)]. Exposure to green space may mitigate tree Pollen Allergy symptom severity but only when the density of allergenic trees is low. Air pollutants contribute to more severe Allergy symptoms. Spatio-temporal tracking allows for a more realistic exposure assessment. Copyright © 2021 Elsevier B.V. All rights reserved.
-
Residential green space and seasonal distress in a cohort of tree Pollen Allergy patients.
International journal of hygiene and environmental health, 2019Co-Authors: Raf Aerts, Michiel Stas, Marijke Hendrickx, Nicolas Dendoncker, Sebastien Dujardin, Naomi Vanlessen, Nicolas Bruffaerts, Lucie Hoebeke, Nelly D. Saenen, An Van NieuwenhuyseAbstract:Abstract Background Residential green space may improve human health, for example by promoting physical activity and by reducing stress. Conversely, residential green space may increase stress by emitting aeroallergens and exacerbating allergic disease. Here we examine impacts of exposure to residential green space on distress in the susceptible subpopulation of adults sensitized to tree Pollen allergens. Methods In a panel study of 88 tree Pollen Allergy patients we analyzed self-reported mental health (GHQ-12), perceived presence of allergenic trees (hazel, alder, birch) near the residence and residential green space area within 1 km distance [high (≥3 m) and low ( Results Short-term distress [mean GHQ-12 score 2.1 (95% confidence interval 1.5–2.7)] was higher in the study population than in the general population [1.5 (1.4–1.7)]. Residential green space had protective effects against short-term distress [high green, per combined surface area of 10 ha: adjusted odds ratio OR = 0.94 (95% confidence interval 0.90–0.99); low green, per 10 ha: OR = 0.85 (0.78–0.93)]. However, distress was higher in patients who reported perceived presence of allergenic trees near their residence [present vs. absent: OR = 2.04 (1.36–3.07)]. Conclusions Perceived presence of allergenic tree species in the neighbourhood of the residence of tree Pollen Allergy patients modulates the protective effect of residential green space against distress during the airborne tree Pollen season.